204078-26-2

Basic information

• Product Name: 4-(IsopropylaMino)benzonitrile
• Synonyms: 4-(IsopropylaMino)benzonitrile
• CAS NO: 204078-26-2
• Molecular Formula: C₁₀H₁₂N₂
• Molecular Weight: 160.21568
• Mol File: 204078-26-2.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(IsopropylaMino)benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(IsopropylaMino)benzonitrile(204078-26-2)
• EPA Substance Registry System: 4-(IsopropylaMino)benzonitrile(204078-26-2)

Safety Data

• Hazardous Substances Data: 204078-26-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(Isopropylamino)benzonitrile is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to be incorporated into the molecular structures of potential drug candidates. Its presence in these molecules can contribute to the drugs' effectiveness in targeting specific biological pathways.
Used in Agrochemical Industry:
In the agrochemical sector, 4-(Isopropylamino)benzonitrile is utilized as a building block in the development of agrochemicals, highlighting its versatility in creating compounds that can address challenges in agriculture.
Used in Antiviral Applications:
4-(Isopropylamino)benzonitrile is employed as an antiviral agent, leveraging its inherent properties to combat viral infections and contribute to the development of treatments for various viral diseases.
Used in Anticancer Research:
4-(IsopropylaMino)benzonitrile is also used in anticancer research, where it is studied for its potential to inhibit cancer cell growth and proliferation, offering a valuable avenue for developing novel cancer therapies.
Used in Drug Discovery and Development:
4-(Isopropylamino)benzonitrile plays a crucial role in drug discovery and development processes, serving as a chemical entity that can be modified and optimized to enhance the potency, selectivity, and safety of new drug molecules.

Upstream product

• 75-30-9 2-iodo-propane 
• 873-74-5 4-Aminobenzonitrile 
• 1194-02-1 4-fluorobenzonitrile 
• 75-31-0 isopropylamine 

Relevant articles and documents

Intramolecular Charge Transfer with the Planarized 4-Aminobenzonitrile 1-tert-Butyl-6-cyano-1,2,3,4-tetrahydroquinoline (NTC6)

Fast and efficient intramolecular charge transfer (ICT) and dual fluorescence is observed with the planarized aminobenzonitrile 1-tert-butyl-6-cyano-1,2,3,4-tetrahydroquinoline (NTC6) in a series of solvents from n-hexane to acetonitrile and methanol. Such a reaction does not take place for the related molecules with 1-isopropyl (NIC6) and 1-methyl (NMC6) groups, nor with the 1-alkyl-5-cyanoindolines with methyl (NMC5), isopropyl (NIC5), or tert-butyl (NTC5) substituents. For these molecules, a single fluorescence band from a locally excited (LE) state is found. The charge transfer reaction of NTC6 is favored by its relatively small energy gap ΔE(S1,S 2), in accordance with the PICT model for ICT in aminobenzonitriles. For the ICT state of NTC6, a dipole moment of around 19 D is obtained from solvatochromic measurements, similar to μe(ICT) = 17 D of 4-(dimethylamino)benzonitrile (DMABN). For NMC5, NIC5, NTC5, NMC6, and NIC6, a dipole moment of around 10 D is determined by solvatochromic analysis, the same as that of the LE state of DMABN. For NTC6 in diethyl ether at -70 °C, the forward ICT rate constant (1.3 × 109 s-1) is much smaller than that of the back reaction (5.9 × 109 s -1), showing that the equilibrium is on the ICT side. The results presented here make clear that ICT can very well take place with a planarized molecule such as NTC6, when ΔE(S1,S2) is sufficiently small, indicating that a perpendicular twist of the amino group relative to the rest of the molecule is not necessary for reaching an ICT state with a large dipole moment. The six-membered alicyclic ring in NMC6, for example, prevents ICT by increasing ΔE(S1,S2) relative to that of DMABN.

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

The present invention provides compounds of formula I: [INSERT FORMULA HERE] or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.

Method of inhibiting neoplastic cells with imidazoquinazoline derivatives

A method for inhibiting neoplasia, particularly cancerous and precancerous lesions by exposing the affected cells to imidazoquinazoline derivatives.

Imidazoquinazoline derivatives

PCT No. PCT/JP97/03023 Sec. 371 Date Apr. 27, 1998 Sec. 102(e) Date Apr. 27, 1998 PCT Filed Aug. 29, 1997 PCT Pub. No. WO98/08848 PCT Pub. Date Mar. 5, 1998Imidazoquinoline derivatives of the formula (wherein X may be O or S) provide selective cyclic guanosine 3',5' monophosphate (cGMP)-specific phosphodiesterase (PDE) inhibitory activity. The compounds are useful for treating or ameliorating cardiovascular disease such as thrombosis, angina pectoris, hypertension, heart failure and arterial sclerosis, as well as asthma, impotence and the like.